Despite progress in some areas, transparency issues remain in Polish healthcare.
New research, from an international group of health policy experts led by the University, reports a mixed picture of transparency in public decisions-making around new medicine approvals in Poland, one of Europe's largest pharmaceutical markets. Despite a troubled relationship with the European Commission, Poland has been hailed as a leader in modernising its assessment systems in establishing whether new drugs represent good value for money and merit significant public investment. Drawing on comprehensive analysis of over 330 scientific drug assessments, the new findings suggest that the Polish Agency for Health Technology Assessment has reached the 'gold' transparency standard set by the National Institute for Health and Care Excellence (NICE) in England. Surprisingly, the Polish Agency has even exceeded NICE in certain ways, such as providing details of the timing of assessment processes. High amount of redacted information. But, this is not a complete success story as there are still areas in which the Polish Agency significantly lags behind NICE. The research finds that scientific assessment reports include a high amount of redacted - or blacked out - information on drug prices, which prevents proper public scrutiny of decisions with huge financial consequences.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
